Study of Risk-Reducing Fallopian Tube Removal with Delayed Ovary Removal Compared to Standard Ovary and Tube Removal in Women at High Genetic Risk for Ovarian Cancer
Led by University Medical Center Nijmegen · Updated on 2026-04-06
3000
Participants Needed
66
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate a new approach to lowering ovarian cancer risk for women with high-risk genetic mutations such as BRCA1, BRCA2, RAD51C, RAD51D, and BRIP1. Traditional prevention involves removing both fallopian tubes and ovaries early, which reduces cancer risk but causes immediate menopause and other health issues. The study explores whether removing only the fallopian tubes first, with delayed removal of the ovaries later, is a safe alternative.
Participants receive either a risk-reducing salpingectomy removal of fallopian tubes followed later by removal of the ovaries or the standard risk-reducing salpingo-oophorectomy removal of both tubes and ovaries at once. Timing for surgeries varies by genetic mutation and age ranges, for example, BRCA1 carriers may have the tubes removed between ages 25 and 40 and ovaries removed by age 45. The study compares these two strategies to assess safety and cancer incidence over time.
Women enrolled in the study will undergo surgeries and will be monitored through follow-up visits including pathology checks six weeks after surgery and long-term tracking of ovarian, pelvic, and breast cancer incidence until age 70. The main outcome measured is the occurrence of high-grade serous ovarian cancer up to age 45 or 50, depending on mutation type. Safety, cancer occurrence, and surgery uptake are carefully recorded over many years, with participation possibly spanning decades.
CONDITIONS
Brief Title
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Research Team
J
Joanne A. de Hullu, MD, PhD
K
Karen H. Lu, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Salpingectomy with Delayed Oophorectomy
Salpingo-oophorectomy (Standard Approach)
What it is
Surgical procedure where both fallopian tubes are removed while retaining the ovaries until a second operation at a later, age-dependent time.
Surgical removal of both fallopian tubes and ovaries in one operation, as established for ovarian cancer risk reduction.
Role in the trial
Investigational prevention strategy, tested for safety and reduction of ovarian cancer risk in women with high-risk mutations.
Active comparator and established preventive surgery for ovarian cancer risk in the same eligible population.
Primary use
To reduce the risk of developing high-grade serous ovarian cancer while potentially delaying premature loss of ovarian hormonal function.
To provide maximal risk reduction for ovarian and fallopian tube cancer by removing both tubes and ovaries at a single operation.
How it is given or performed
Initial laparoscopic removal of both fallopian tubes. Ovaries are preserved and removed by a separate operation years later, according to the patient's age and gene mutation.
Laparoscopic surgery to remove both fallopian tubes and both ovaries in one procedure, timed according to gene mutation and risk stratification.
Evidence status
Evidence for reduced ovarian cancer risk and safety is not yet established; outcome data from randomized and prospective studies are awaited.
Extensive long-term observational and interventional evidence supports its effectiveness in reducing ovarian and fallopian tube cancer risk in high-risk women.
Important limitations
Cancer prevention benefit and long-term safety are not yet determined. There are risks from multiple surgeries, and the impact of delaying oophorectomy on cancer risk is unknown.
While highly effective for cancer risk reduction, this procedure leads to immediate surgical menopause and associated symptoms and long-term health effects from loss of ovarian hormones.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 25Years - 50Years
FEMALE
Eligibility Criteria
You may qualify if you...
Women with a confirmed pathogenic BRCA1, BRCA2, RAD51C, RAD51D, or BRIP1 germline mutation
Age at inclusion: 25-40 years for BRCA1, 25-45 years for BRCA2, and 25-50 years for RAD51C, RAD51D, BRIP1
Completed childbearing
At least one fallopian tube present
May have a personal history of non-ovarian cancer
Able to provide informed consent according to regulations
You will not qualify if you...
Postmenopausal status (natural or treatment-induced)
Planning risk-reducing oophorectomy within two years after salpingectomy
Legally incapable of consent
Prior bilateral salpingectomy
Personal history of ovarian, fallopian tube, or peritoneal cancer
Currently diagnosed with or being treated for any malignant disease
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Risk-reducing Salpingectomy
Duration - Occurs once according to age guidelines (BRCA1: 25-40 years, BRCA2: 25-45 years, others: 25-50 years)
Participants undergo risk-reducing salpingectomy after completion of childbearing according to their genetic mutation and age group.
1 surgical visit
Delayed Risk-reducing Oophorectomy
Duration - Occurs once according to age guidelines (BRCA1: by 45 years, BRCA2: by 50 years, others: by 55 years)
Participants undergo delayed risk-reducing oophorectomy at a later age based on their genetic mutation, as an alternative to immediate oophorectomy.
1 surgical visit
Risk-reducing Salpingo-Oophorectomy
Duration - Occurs once according to age guidelines (BRCA1: by 40 years, BRCA2: by 45 years, others: by 50 years)
Participants may undergo risk-reducing salpingo-oophorectomy as an alternative standard care according to their genetic mutation and age.
1 surgical visit
Long-term Monitoring
Duration - Up to age 70 depending on individual risk and intervention arm
Participants are monitored long-term to assess ovarian and other cancer incidence and uptake of risk-reducing procedures.
Follow-up visits as scheduled over years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Study of Preventive Surgery Options for Women with High Genetic Risk of Hereditary Ovarian Cancer
Observing Effects on Cancer Risk, Ovarian Function, and Quality of Life
Study Comparing the Pharmacokinetics and Safety of BR2022 and BR2022-1
in Female Patients with BRCA-Mutated Advanced Ovarian Cancer
Using Olaparib Treatment
Phase 1 Study of CD70-targeted CAR-T Cells for Advanced or Metastatic CD70-positive Gynecologic Cancer
Phase I Study of CD70-targeted CAR-T Therapy for Adults with Advanced or Metastatic CD70-positive Solid Tumors
Open Multicenter Study of SHR-A1811 Combined With Chemotherapy for Treating Platinum Sensitive Recurrent Ovarian Cancer
Phase II Study of SYS6041 Combination Therapy Evaluating Safety and Efficacy in Recurrent Ovarian Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Miranda P Steenbeek, Majke H D van Bommel, Joanna intHout...